AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States.
The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance.
It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite.
It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Country | United States |
IPO Date | May 22, 2012 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 107 |
CEO | Joseph Michael Burnett |
Contact Details
Address: 120 S. Sierra Avenue Solana Beach, California United States | |
Website | https://www.clearpointneuro.com |
Stock Details
Ticker Symbol | CLPT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001285550 |
CUSIP Number | 18507C103 |
ISIN Number | US18507C1036 |
Employer ID | 58-2394628 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Joseph Michael Burnett | President, Chief Executive Officer & Director |
Danilo D'Alessandro | Chief Financial Officer |
Mazin Sabra | Chief Operating Officer |
Ellisa Cholapranee J.D. | General Counsel & Secretary |
Jacqueline Keller | Vice President of Marketing |
Jeremy Stigall | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |